199 related articles for article (PubMed ID: 24209510)
1. Cytosolic and nuclear caspase-8 have opposite impact on survival after liver resection for hepatocellular carcinoma.
Koschny R; Brost S; Hinz U; Sykora J; Batke EM; Singer S; Breuhahn K; Stremmel W; Walczak H; Schemmer P; Schirmacher P; Ganten TM
BMC Cancer; 2013 Nov; 13():532. PubMed ID: 24209510
[TBL] [Abstract][Full Text] [Related]
2. Hepatocyte expression of TRAIL pathway regulators correlates with histopathological and clinical parameters in chronic HCV infection.
Brost S; Zimmermann A; Koschny R; Sykora J; Stremmel W; Schirmacher P; Walczak H; Ganten TM
Pathol Res Pract; 2014 Feb; 210(2):83-91. PubMed ID: 24268735
[TBL] [Abstract][Full Text] [Related]
3. WHO grade related expression of TRAIL-receptors and apoptosis regulators in meningioma.
Koschny R; Krupp W; Xu LX; Mueller WC; Bauer M; Sinn P; Keller M; Koschny T; Walczak H; Bruckner T; Ganten TM; Holland H
Pathol Res Pract; 2015 Feb; 211(2):109-16. PubMed ID: 25481563
[TBL] [Abstract][Full Text] [Related]
4. TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies.
Koehler BC; Urbanik T; Vick B; Boger RJ; Heeger S; Galle PR; Schuchmann M; Schulze-Bergkamen H
World J Gastroenterol; 2009 Dec; 15(47):5924-35. PubMed ID: 20014456
[TBL] [Abstract][Full Text] [Related]
5. COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
Yamanaka Y; Shiraki K; Inoue T; Miyashita K; Fuke H; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Int J Mol Med; 2006 Jul; 18(1):41-7. PubMed ID: 16786154
[TBL] [Abstract][Full Text] [Related]
6. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
[TBL] [Abstract][Full Text] [Related]
7. Expression, cellular distribution, and prognostic relevance of TRAIL receptors in hepatocellular carcinoma.
Kriegl L; Jung A; Engel J; Jackstadt R; Gerbes AL; Gallmeier E; Reiche JA; Hermeking H; Rizzani A; Bruns CJ; Kolligs FT; Kirchner T; Göke B; De Toni EN
Clin Cancer Res; 2010 Nov; 16(22):5529-38. PubMed ID: 20889918
[TBL] [Abstract][Full Text] [Related]
8. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
Yamamoto T; Nagano H; Sakon M; Wada H; Eguchi H; Kondo M; Damdinsuren B; Ota H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Dono K; Umeshita K; Nakamori S; Yagita H; Monden M
Clin Cancer Res; 2004 Dec; 10(23):7884-95. PubMed ID: 15585621
[TBL] [Abstract][Full Text] [Related]
9. The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
Miyashita K; Shiraki K; Fuke H; Inoue T; Yamanaka Y; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Int J Mol Med; 2006 Aug; 18(2):249-56. PubMed ID: 16820931
[TBL] [Abstract][Full Text] [Related]
10. TRAIL expression levels in human hepatocellular carcinoma have implications for tumor growth, recurrence and survival.
Piras-Straub K; Khairzada K; Trippler M; Baba HA; Kaiser GM; Paul A; Canbay A; Weber F; Gerken G; Herzer K
Int J Cancer; 2015 Feb; 136(4):E154-60. PubMed ID: 25123818
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines.
Yamanaka T; Shiraki K; Sugimoto K; Ito T; Fujikawa K; Ito M; Takase K; Moriyama M; Nakano T; Suzuki A
Hepatology; 2000 Sep; 32(3):482-90. PubMed ID: 10960439
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer.
Ganten TM; Sykora J; Koschny R; Batke E; Aulmann S; Mansmann U; Stremmel W; Sinn HP; Walczak H
J Mol Med (Berl); 2009 Oct; 87(10):995-1007. PubMed ID: 19680616
[TBL] [Abstract][Full Text] [Related]
13. TRAIL enhances apoptosis of human hepatocellular carcinoma cells sensitized by hepatitis C virus infection: therapeutic implications.
Jang JY; Kim SJ; Cho EK; Jeong SW; Park EJ; Lee WC; Lee SH; Kim SG; Kim YS; Kim HS; Kim BS; Lin W; Chung RT
PLoS One; 2014; 9(6):e98171. PubMed ID: 24927176
[TBL] [Abstract][Full Text] [Related]
14. Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms.
Charette N; De Saeger C; Horsmans Y; Leclercq I; Stärkel P
Cell Death Dis; 2013 Jan; 4(1):e471. PubMed ID: 23348585
[TBL] [Abstract][Full Text] [Related]
15. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
16. Different apoptotic regulation of TRAIL-caspase pathway in HBV- and HCV-related hepatocellular carcinoma.
Yano Y; Hayashi Y; Nakaji M; Nagano H; Seo Y; Ninomiya T; Yoon S; Wada A; Hirai M; Kim SR; Yokozaki H; Kasuga M
Int J Mol Med; 2003 Apr; 11(4):499-504. PubMed ID: 12632104
[TBL] [Abstract][Full Text] [Related]
17. Thymoquinone upregulates TRAIL/TRAILR2 expression and attenuates hepatocellular carcinoma in vivo model.
Helmy SA; El-Mesery M; El-Karef A; Eissa LA; El Gayar AM
Life Sci; 2019 Sep; 233():116673. PubMed ID: 31336121
[TBL] [Abstract][Full Text] [Related]
18. Notch1 signaling sensitizes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human hepatocellular carcinoma cells by inhibiting Akt/Hdm2-mediated p53 degradation and up-regulating p53-dependent DR5 expression.
Wang C; Qi R; Li N; Wang Z; An H; Zhang Q; Yu Y; Cao X
J Biol Chem; 2009 Jun; 284(24):16183-16190. PubMed ID: 19376776
[TBL] [Abstract][Full Text] [Related]
19. Thyroid hormone receptors promote metastasis of human hepatoma cells via regulation of TRAIL.
Chi HC; Chen SL; Liao CJ; Liao CH; Tsai MM; Lin YH; Huang YH; Yeh CT; Wu SM; Tseng YH; Chen CY; Tsai CY; Chung IH; Chen WJ; Lin KH
Cell Death Differ; 2012 Nov; 19(11):1802-14. PubMed ID: 22576662
[TBL] [Abstract][Full Text] [Related]
20. Rocaglamide overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells by attenuating the inhibition of caspase-8 through cellular FLICE-like-inhibitory protein downregulation.
Luan Z; He Y; He F; Chen Z
Mol Med Rep; 2015 Jan; 11(1):203-11. PubMed ID: 25333816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
